CN105663900B - 一种用于改善肝硬化营养状态的药膳 - Google Patents
一种用于改善肝硬化营养状态的药膳 Download PDFInfo
- Publication number
- CN105663900B CN105663900B CN201610128556.8A CN201610128556A CN105663900B CN 105663900 B CN105663900 B CN 105663900B CN 201610128556 A CN201610128556 A CN 201610128556A CN 105663900 B CN105663900 B CN 105663900B
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- liver
- poria cocos
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 64
- 235000005911 diet Nutrition 0.000 title claims abstract description 34
- 230000037213 diet Effects 0.000 title claims abstract description 32
- 235000016709 nutrition Nutrition 0.000 title description 9
- 230000035764 nutrition Effects 0.000 title description 3
- 235000013305 food Nutrition 0.000 claims abstract description 31
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 25
- 235000003715 nutritional status Nutrition 0.000 claims abstract description 25
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 24
- 244000197580 Poria cocos Species 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241001247821 Ziziphus Species 0.000 claims description 22
- 235000007164 Oryza sativa Nutrition 0.000 claims description 17
- 235000009566 rice Nutrition 0.000 claims description 17
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 14
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 14
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 14
- 241000287828 Gallus gallus Species 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 13
- 238000003672 processing method Methods 0.000 claims description 11
- 206010016654 Fibrosis Diseases 0.000 claims description 8
- 230000007882 cirrhosis Effects 0.000 claims description 7
- 230000035622 drinking Effects 0.000 claims description 7
- 241000209094 Oryza Species 0.000 claims 14
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 claims 10
- 240000000038 Ziziphus mauritiana Species 0.000 claims 10
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims 10
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims 10
- 239000012528 membrane Substances 0.000 claims 9
- 238000001035 drying Methods 0.000 claims 5
- 235000002555 Citrus medica var sarcodactylis Nutrition 0.000 claims 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 53
- 210000000952 spleen Anatomy 0.000 abstract description 40
- 239000003814 drug Substances 0.000 abstract description 36
- 240000008467 Oryza sativa Japonica Group Species 0.000 abstract description 19
- 244000179970 Monarda didyma Species 0.000 abstract description 15
- 235000010672 Monarda didyma Nutrition 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 12
- 240000005717 Dioscorea alata Species 0.000 abstract description 11
- 230000006870 function Effects 0.000 abstract description 11
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 235000015097 nutrients Nutrition 0.000 abstract description 6
- 230000008929 regeneration Effects 0.000 abstract description 6
- 238000011069 regeneration method Methods 0.000 abstract description 6
- 208000004880 Polyuria Diseases 0.000 abstract description 5
- 230000035619 diuresis Effects 0.000 abstract description 5
- 238000009098 adjuvant therapy Methods 0.000 abstract description 3
- 230000035790 physiological processes and functions Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 102000007562 Serum Albumin Human genes 0.000 abstract description 2
- 108010071390 Serum Albumin Proteins 0.000 abstract description 2
- 235000013339 cereals Nutrition 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 210000005228 liver tissue Anatomy 0.000 abstract description 2
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 230000004962 physiological condition Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000007812 deficiency Effects 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 208000002672 hepatitis B Diseases 0.000 description 13
- 102000009027 Albumins Human genes 0.000 description 12
- 108010088751 Albumins Proteins 0.000 description 12
- 235000002723 Dioscorea alata Nutrition 0.000 description 12
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 12
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 12
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 12
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 12
- 235000004879 dioscorea Nutrition 0.000 description 12
- 206010000060 Abdominal distension Diseases 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 9
- 239000010931 gold Substances 0.000 description 9
- 229910052737 gold Inorganic materials 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 208000019423 liver disease Diseases 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000032023 Signs and Symptoms Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 208000002720 Malnutrition Diseases 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 235000000824 malnutrition Nutrition 0.000 description 4
- 230000001071 malnutrition Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 description 4
- 235000011888 snacks Nutrition 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010057573 Chronic hepatic failure Diseases 0.000 description 2
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 235000007056 Dioscorea composita Nutrition 0.000 description 2
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 2
- 208000010334 End Stage Liver Disease Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010033372 Pain and discomfort Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 208000019229 Spleen disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009798 acute exacerbation Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000011444 chronic liver failure Diseases 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- OEBRKCOSUFCWJD-UHFFFAOYSA-N dichlorvos Chemical compound COP(=O)(OC)OC=C(Cl)Cl OEBRKCOSUFCWJD-UHFFFAOYSA-N 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 208000027140 splenic disease Diseases 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- HXVZGASCDAGAPS-UHFFFAOYSA-N MAMC Natural products CC1=CC(=O)OC2=CC(OC(=O)C)=CC=C21 HXVZGASCDAGAPS-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明提供一种用于改善肝硬化营养状态的药膳,所用原料为茯苓、薏苡仁、山药、佛手、鸡内金、大枣、粳米具有健脾祛湿、疏肝理气之功。药食同源借助于食物本身的特性,不仅能为患者提供机体需要的部分能量和营养成分,而且通过中药成分的健脾祛湿,行气利水作用,使三焦的通行元气、疏通水道、运行水谷功能达到最佳,从而消除病理因素,改善肝脏的生理功能,形成有利于肝脏组织修复的生理条件,对肝硬化患者的病情状况产生了良性辅助治疗作用;能提高血浆白蛋白、促进肝脏再生及肝脏功能的恢复方面的作用,为肝硬化失代偿期患者的辅助治疗提供一种简单易行、经济实惠、安全有效的新方法。经多年临床实践,其有效率为92.7%。
Description
技术领域:
本发明涉及药食同源食品领域,特别是一种用于改善肝硬化营养状态的药膳,可以显著改善患者氧化供能比例,改善蛋白代谢,提高白蛋白水平。
背景技术:
肝硬化为弥漫性纤维组织增生和肝细胞结节状再生,肝脏正常结构遭到破坏,以致引起以肝功能减退和门脉高压为主要表现的临床症状。欧洲肝病学会(EASL)2012年指南中指出,未经治疗的慢性乙型肝炎(CHB)患者,5年累计肝硬化发生率为8%~20%,代偿期肝硬化患者5年累计失代偿期肝硬化发生率约20%,而进展为失代偿期肝硬化患者,若未经治疗,则其5年生存率仅为14%~35%,而在肝硬化患者中,每年原发性肝细胞癌(HCC)发生率为2%~5%。我国是全球肝硬化发病率、死亡率最高的国家之一。肝硬化患者病情反复,迁延不愈,失代偿后可出现各种并发症,严重影响其生活质量,给患者心理造成极大的压力。严重地威胁着患者的生命及生存质量。因而有效的改善肝硬化失代偿期患者营养状态,减少患者并发症,提高生存质量,改善临床结局和预后,是临床目前亟待解决的核心问题之一。
肝硬化患者均有不同程度的营养不良,其营养不良风险的原因主要有摄入减少;消化吸收障碍;消耗增加;合成不足等而不合理的膳食使营养不良更加明显,且可增加肝脏负担,降低肝细胞对致病因素的抵抗力,使肝功能进一步减退,导致病情恶化。大量研究表明,许多肝硬化等终末期肝病(ESLD)患者并非死于肝病本身,而是死于营养不良及由此导致的顽固性腹水、反复感染、肝脏再生不良等并发症。肝脏是糖、脂肪、蛋白质等许多物质代谢的中枢器官,肝硬化必然导致肝脏代谢功能下降从而影响到全身状况。研究表明,肝硬化患者存在明显代谢异常,禁食一夜很容易引起机体利用氨基酸来实现糖异生。由于肝细胞数量与合成能力不足,肝糖原储备严重下降,因此骨骼肌的氨基酸动员增加,以满足机体对葡萄糖的需要,这种变化相当于在正常人禁食三天的情况。
另有研究显示,给予肝硬化患者夜间加餐(late evening snack, LES),可以显著改善患者氧化供能比例,改善蛋白代谢,提高白蛋白水平。目前认为,夜间加餐内容应以碳水化合物为主,加餐支链氨基酸制剂亦可提高血清蛋白水平,但由于口感差,患者依从性会有所降低。纽娃®(Noveliver®)是一种针对肝病患者设计的新型复合营养素,富含蛋白质、氨基酸、维生素、微量元素、叶酸、有机硒等多种物质。前期研究显示,给予肝硬化大鼠纽娃®肝营养素干预,可以较快提升白蛋白水平,改善纤维化程度。但纽娃费用昂贵,大部分患者负担不起。
肝硬化属中医“鼓胀”“肝积”“黄疸”范畴,为“风、痨、臌、膈”四大难症之一。由于患者病变日久,正气不足,邪实内滞,往往寒热错杂,虚实兼具,所以治疗很棘手。一般认为该病初起为湿热疫毒蕴阻中焦,肝失疏泄,气滞血瘀,进而横逆乘脾,脾失健运。肝脾在生理上有着密切的联系。脾土居中焦,为气机升降的枢纽,气血生化之源,主运化水谷精微;脾主升清,助于肝的疏泄;胃主降浊,利于胆汁排泄。生理上脾胃正常的运化和升降功能有赖于肝气的疏泄,肝的疏泄功能正常,气机调畅,则脾胃升降有序,运化功能健全。同时,脾胃为后天之本,气血生化之源,脾气健运则生化有源,肝血充盛。病理上脾病可影响于肝,脾气不足,气血生化无源,或脾不统血,失血过多,可累及于肝,形成肝血不足。脾失健运,水湿内停,日久蕴积生热,湿热蕴蒸,使肝胆疏泄不利,可形成黄疸。反之,肝病也影响于脾,肝失疏泄,致土壅木郁,形成肝脾不调或肝胃不和的证候。由此可见,脾病传肝,肝病及脾,肝脾两脏在病理上相互影响。本虚标实,虚实夹杂是形成肝硬化失代偿期的基本病机,主要为脾虚失运。本虚是脾气虚、肝阴虚、肾阴虚,标实是气滞、血瘀、水停,病位在肝,与脾、肾关系密切。初病在肝,多表现为肝胆湿热,久则肝郁脾虚,脾虚湿阻,水湿蕴结,久病及肾,肝肾两虚,脾虚是肝硬化失代偿期演变重要环节。
发明内容
综上所述,本发明之目的就是提供一种用于改善肝硬化营养状态的药膳,发明伴随着医学模式的改变,人们在追求临床疗效的同时,更注重“药食同源、药补不如食补”的思想。古人素有“医食同源”“寓医于食”的观点,李时珍在《本草纲目》中记载了300 多种日常食物的疗效,并提出多种食疗药膳方。中医食疗既不同于药物疗法,也与普通膳食有差别,它利用食物性味偏颇的特性,有针对性地用于某些病证的治疗或辅助治疗,调整体内器官组织的生理机能,使之趋于平衡,有助于疾病的治疗和身心的康复。名医张锡纯说:“食疗不但疗病,并可充饥,不但充饥,更可适口,用之对症,病自渐愈。”
本发明的技术方案是通过以下方式实现的:
一种用于改善肝硬化营养状态的药膳,是由按重量份计的茯苓5-15份,山药5-15份,薏苡仁5-15份,佛手5-15份,鸡内金1-6份,大枣3-7个,粳米2-8份制成;所述的药膳的加工方法包括以下步骤:
1)按配方选取原料茯苓,山药,薏苡仁,佛手,鸡内金,大枣,粳米,大枣去核后经烘干,备用;
2)将步骤1)的原料用粉碎机加工成粉;
3)在睡前半小时或晚9-10点,将步骤2)加工的粉用开水调成150-200ml米糊饮用;
4)夜间加餐应持续3个月。
进一步,所述的一种用于改善肝硬化营养状态的药膳,是由按重量份计的茯苓7-10份,山药7-10份,薏苡仁7-10份,佛手7-10份,鸡内金3-5份,大枣4-5个,粳米3-5份制成。
进一步,所述的一种用于改善肝硬化营养状态的药膳,是由按重量份计的茯苓12-13份,山药12-13份,薏苡仁12-13份,佛手12-13份,鸡内金2-4份,大枣4-5个,粳米4-6份制成。
进一步,所述的一种用于改善肝硬化营养状态的药膳,是由按重量份计的茯苓8份,山药8份,薏苡仁8份,佛手8份,鸡内金4份,大枣6个,粳米7份制成。
进一步,所述的一种用于改善肝硬化营养状态的药膳,是由按重量份计的茯苓14份,山药14份,薏苡仁14份,佛手14份,鸡内金3份,大枣4个,粳米4份制成。
本发明的药理依据是:
茯苓性甘、淡、平;入心、脾、肾经,具有渗湿利尿、和胃健脾、宁心安神、抑菌、增强机体抗病能力及降低血糖的功效;
山药性味甘、平,入肺、脾、肾经,有补脾养胃、生津益肺、补肾涩精的功效;山药既是一味补益性中药,又是日常佳蔬,早在《神农本草经》中已将其列为“上品”药材,认为其“补中益气力,长肌肉,久服耳目聪明,轻身,不饥延年”;营养分析表明,山药富含淀粉、蛋白质、氨基酸、维生素等多种营养成分,山药所含的消化酶能促进蛋白质和淀粉的分解,有利于食物的消化吸收。山药所含的脱氢表雄酮,对人体有特殊的保健作用,有预防动脉硬化和肥胖病的功效;
薏苡仁其性微寒,味甘、淡,归脾、胃,肺经;有健脾渗湿,除痹止泻的功效;现代药理学研究中,薏苡仁的主要活性成分包括糖类、酯类、不饱和脂肪酸类及内酰胺类等,具有抗肿瘤、提高机体免疫力、降血糖、抗炎镇痛等多方面的作用;药性平和,食药兼顾,在临床、养生等方面皆占据重要位置;
佛手性温,味辛,苦、酸;入肝、脾、肺经;有疏肝理气、和胃止痛之功效;研究发现,佛手具有免疫调节、抗氧化及促进胃肠蠕动作用;
鸡内金含胃激素,角蛋白,微量胃蛋白酶,淀粉酶和多种氨基酸,具有健脾消食的功效,鸡内金作为胃药中助消化类和增强胃动力类药物,应用前景广阔,且鸡内金为药食同源的天然材料,无毒无害,开发成天然保健食品、药膳、组方应用均能发挥其更大的药用价值;
大枣性温味甘,归脾、胃经;补中益气,养血安神,缓和药性;大枣进一步的药理研究表明, 大枣多糖具有明显的行血、止血、利水、通经活络之功效, 同时具有明显的抗补体活性和促进淋巴细胞增殖的作用, 它能有效增强机体免疫力。枣肉多糖能增强小鼠体液免疫和细胞免疫功能, 并对放射性损伤有一定的保护作用, 是免疫增强剂;研究证实, 大枣多糖具有抗癌和抗艾滋病等生理活性, 其药用价值倍受关注;
粳米性硬少粘,气味苦、甘、平、无毒,入脾、胃经;宋代有人云:粳米以晚白米为第一,……平和五脏,补益胃气,其功莫逮;唐代医药学家孙思逸在《千金方·食治》中强调说,粳米能养胃气、长肌肉;《食鉴本草》也认为,粳米有补脾胃、养五脏、壮气力的良好功效。 粳米是我国南方人民的主食,含有大量碳水化合物,约占 79% 是热量的主要来源;粳米中的蛋白质虽然只占7%,但因吃量很大,所以仍然是蛋白质的重要来源;粳米所含人体必需氨基酸也比较全面,还含有脂肪、钙、磷、铁及B族维生素等多种营养成分。
本发明是经过多年临床实践,发现以健脾为主的中药能够有效的改善患者的营养水平,所用中药主要为茯苓、薏苡仁、山药、佛手、鸡内金、大枣、粳米具有健脾祛湿、疏肝理气之功。药食同源借助于食物本身的特性,不仅能为患者提供机体需要的部分能量和营养成分,而且通过中药成分的健脾祛湿,行气利水作用,使三焦的通行元气、疏通水道、运行水谷功能达到最佳,从而消除病理因素,改善肝脏的生理功能,形成有利于肝脏组织修复的生理条件,对肝硬化患者的病情状况产生了良性辅助治疗作用(P<0.05)。三焦通行三气,历经诸脏腑,三焦通百脉,其当令亥时-寅时(夜间21:00-23:00),这段时间是人体细胞休养生息、推陈出新的时间;子时-丑时(夜间23:00-凌晨3点)是肝胆经当令时间,肝主藏血、主疏泄,人卧血归于肝。对肝硬化患者夜间加餐则更有助于人体营养物质吸收,为肝细胞修复再生提供原材料。《金贵要略》云:“见肝之病,知肝传脾,当先实脾”,强调了治未病及既病防变的理念。“有一分胃气,则有一分生机”,肝硬化患者治疗中健脾顾护胃气尤为重要。通过创新性挖掘古代文献,结合肝病科自身特点,基于肝病实脾理论,运用药食同源对肝硬化患者营养状态、生活质量的干预研究,通过观察患者症状、体重指数(BMI),三头肌皮褶厚度(TSF),上臂肌围(MAMC),握力检查等营养状态及并发症减少。在长期的临床观察中发现,在“药食同源”理论指导下,肝硬化患者夜间加餐,生活质量得到提高,且该方法简便易行、费用低、患者易于接受。
本发明的有益效果是:
本发明对肝硬化失代偿期患者采用“药食同源”,观察对肝硬化失代偿期患者营养状态、肝功能及生存质量的影响,用于改善肝硬化营养状态的药膳,能提高血浆白蛋白、促进肝脏再生及肝脏功能的恢复方面的作用,为肝硬化失代偿期患者的辅助治疗提供一种简单易行、经济实惠、安全有效的新方法。本发明经多年临床实践,其有效率为92.7%。
具体实施方式:
以下结合实施例对本发明作进一步的详细说明。
实施例1
一种用于改善肝硬化营养状态的药膳,是由按重量份计的茯苓5-15份,山药5-15份,薏苡仁5-15份,佛手5-15份,鸡内金1-6份,大枣3-7个,粳米2-8份制成;所述的药膳的加工方法包括以下步骤:
1)按配方选取原料茯苓,山药,薏苡仁,佛手,鸡内金,大枣,粳米,大枣去核后经烘干,备用;
2)将步骤1)的原料用粉碎机加工成粉;
3)在睡前半小时或晚9-10点,将步骤2)加工的粉用开水调成150-200ml米糊饮用;
4)夜间加餐应持续3个月。
实施例2
一种用于改善肝硬化营养状态的药膳,是由按重量份计的茯苓7-10份,山药7-10份,薏苡仁7-10份,佛手7-10份,鸡内金3-5份,大枣4-5个,粳米3-5份制成;所述的药膳的加工方法同实施例1。
实施例3
一种用于改善肝硬化营养状态的药膳,是由按重量份计的茯苓12-13份,山药12-13份,薏苡仁12-13份,佛手12-13份,鸡内金2-4份,大枣4-5个,粳米4-6份制成;所述的药膳的加工方法同实施例1。
实施例4
一种用于改善肝硬化营养状态的药膳,是由按重量份计的茯苓8份,山药8份,薏苡仁8份,佛手8份,鸡内金4份,大枣6个,粳米7份制成;所述的药膳的加工方法同实施例1。
实施例5
一种用于改善肝硬化营养状态的药膳,其特征在于,按重量份计的茯苓14份,山药14份,薏苡仁14份,佛手14份,鸡内金3份,大枣4个,粳米4份制成;所述的药膳的加工方法同实施例1。
本发明应用于临床收到良好的效果,总有效率为92.7%;具体临床资料如下:
一.诊断标准
本研究对肝硬化失代偿期患者采用“药食同源”新型LES,观察对肝硬化失代偿期患者营养状态、肝功能及生存质量的影响,研究新型LES在改善营养状态,提高血浆白蛋白、促进肝脏再生及肝脏功能的恢复方面的作用,为肝硬化失代偿期患者的辅助治疗探索简单易行、经济实惠、安全有效的新方法。
选取2014年1月至2015年12月符合2012年9月中华医学会传染病与寄生虫病学分会、肝病学分会联合修订的《病毒性肝炎防治方案》中的关于肝硬化失代偿期住院患者110例,采用区组随机化方法,将患者分为两组,每组55例,LES研究组为“基础治疗+药食同源新型LES”,对照组为“基础治疗”,疗程2周,随访3个月,分别从营养相关评分、Child-Pugh评分、肝功能、人体测量学指标、慢性肝病生存质量、并发症发生率等方面,评价药食同源新型LES对肝硬化失代偿期患者营养状态的疗效。
1.研究对象
1.1西医肝硬化诊断标准
病例参照2012年9月中华医学会传染病与寄生虫病学分会、肝病学分会联合修订的《病毒性肝炎防治方案》中的关于肝硬化的诊断标准,为排除其他病因及治疗对临床疗效的影响,本研究只纳入乙肝肝硬化失代偿期患者。
1.2中医证候诊断标准
参照2011年在太原召开的中国中西医结合学会消化系统疾病专业委员会第十五届学术交流会,讨论制定的《肝硬化中西医结合诊疗共识》的辨证分型为标准,具备主症及次症一项以上,结合舌象、脉象,即可诊断。
1.3样本量的计算
依据统计学最小样本量的指定要求,每个治疗组样本数是50例,考虑10%的脱失率,每组需样本55例,共计110例,LES研究组55例,对照组55例。
2.研究方法
2.1试验设计类型:随机、对照试验设计。
2.1.1随机:采用区组随机化方法。借助SAS统计分析系统PROCPLAN过程语句,给定种子数,产生110例随机编号。
2.1.2依据标准,采用随机分组,依据患者住院顺序的先后将患者分两组,LES研究组采用为“基础治疗+药食同源新型LES”,对照组采用“基础治疗”。
基础治疗:保肝降酶等治疗,两组均按照科室诊疗常规进行;对符合2010年版《慢性乙型肝炎防治指南》中肝硬化抗病毒指征的患者给予核苷(酸)类似物抗病毒治疗。有抗病毒指征,但不愿意或不能接受抗病毒治疗的患者退出研究。
3.观察指标
3.1生物学指标一般项目:受试者姓名、试验开始日期、住址、联系电话、姓名。
生物学指标 (1)人口学资料:包括性别、年龄、身高、体重、民族等;(2)生命体征:体温、心率、呼吸、血压、异常症状体征等,如有异常或特诉情况下随时记录。
3.2疗效性指标
参照《中药新药临床研究指导原则》(郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:143-151)制定如下表1:
表1
3.2.3 证候疗效评价
所有症状都分为无、轻、中、重四级,在主症分别记0、2、4、6,在次证则分别记0、1、2、3分。对于舌脉则分为正常和非正常两级,在主症分别记0、2分,在次症分别记0、1分。证候疗效判定标准的计算方法,参照《中药新药临床研究指导原则》疗效评定标准,采用尼莫地平法计算。疗效指数(%)=[(治疗前积分一治疗后积分)/治疗前积分]x 100%。
3.2.3.1临床缓解:症状和体征明显改善(疗效指数≥95%);
3.2.3.2显效:症状和体征明显改善(70%≤疗效指数<95%);
3.2.3.3有效:症状和体征有改善(30%≤疗效指数<70%);
3.2.3.4无效:症状和体征无明显减轻或加重者(疗效指数<30%)。
采用SPSS19.0软件进行统计学处理。所有计量资料数据均以均数±标准差表示,计量资料采用方差分析,计数资料采用卡方检验或秩和检验,P<0.05将被认为所检验的差别有统计学意义。
结果见表2
表2 观察组与对照组总有效率比较
组别 | 例数 | 显效 | 有效 | 无效 | 有效率% |
观察组 | 55 | 42 | 9 | 4 | 92.7 |
对照组 | 55 | 31 | 6 | 8 | 69.1 |
不良反应:所有病例未发现明显的不良反应。
典型病例
1.吕某某,男,出租车司机,36岁。2015年因右胁胀痛不适、腹胀、乏力、身目尿黄、纳差为主诉入院。入院症状:身目黄染、尿黄、右胁胀痛不适、高度腹胀乏力、懒言少语、纳差、大便溏,3-4次/日,舌质淡胖、脉沉细。彩超示:肝硬化,具有乙肝病史。生化检查:白蛋白20g/L。中医诊断为肝积,证型为肝郁脾虚型,西医诊断为:⑴乙肝肝硬化失代偿期(慢性活动加重期);⑵低蛋白血症(20g/L)。入院后给予常规的保肝降酶、营养支持治疗,随机给予药膳夜间加餐三周,患者身目尿黄明显减轻,白蛋白升高(30g/L),上述症状明显好转,患者好转出院。
2.王女士,女,农民,62岁。2015年因高度腹胀、乏力、纳差、四肢不温为主诉入院。入院症状:面色黧黑、呼吸困难,腹胀纳差、食后胀甚、倦怠乏力、畏寒,大便稀,舌质淡胖、脉弦细无力。彩超示:肝硬化,具有乙肝病史。生化检查:白蛋白26g/L。中医诊断为肝积,证型为肝郁脾虚,西医诊断为:⑴乙肝肝硬化失代偿期;⑵慢性乙型肝炎急性加重期。入院后给予常规的保肝降酶、营养支持,随机给予药膳夜间加餐两周,尿量增加,白蛋白升高32g/L。上述症状明显好转,患者出院。
3.赵某某,男,农民,42岁。2014年11月份因高度腹胀、高度黄疸、恶心呕吐、少气懒言、不欲饮食为主诉入院。入院症状:身目俱黄、倦怠乏力、静卧懒言,腹胀。舌质淡苔白腻、脉弦滑。彩超示:肝硬化,具有乙肝病史。生化检查:胆红素:625mol/L,白蛋白23g/L。中医诊断为肝积,证型为肝郁脾虚,西医诊断为:⑴乙肝肝硬化失代偿期;⑵慢性乙型肝炎急性加重期。入院后给予抗感染、人工肝治疗及保肝降酶、营养支持,即给予药膳夜间加餐四周,白蛋白升高34g/L。上述症状明显好转,住院28天,患者出院。随访1年来,病人生化检查正常。
4.李某某,女,干部,62岁。2014年6月份因腹胀、乏力活动后加重,纳差为主诉入院。入院症状:面色晦暗,腹胀,乏力,小便少。舌质淡苔白、脉弦滑。彩超示:肝硬化,中等量腹水。生化检查:白蛋白27g/L。中医诊断为肝积(鼓胀),证型为肝郁脾虚,西医诊断为:⑴乙肝肝硬化失代偿期;⑵腹水。入院后给予保肝降酶、营养支持,配合给予药膳夜间加餐两周,白蛋白升高30g/L。上述症状明显好转,患者出院。
Claims (5)
1.一种用于改善肝硬化营养状态的药膳,其特征在于,是由按重量份计的茯苓5-15份,山药5-15份,薏苡仁5-15份,佛手5-15份,鸡内金1-6份,大枣3-7个,粳米2-8份制成;所述的药膳的加工方法包括以下步骤:
1)按配方选取原料茯苓,山药,薏苡仁,佛手,鸡内金,大枣,粳米,大枣去核后经烘干,备用;
2)将步骤1)的原料用粉碎机加工成粉;
3)在睡前半小时或晚9-10点,将步骤2)加工的粉用开水调成150-200ml米糊饮用;
4)夜间加餐应持续3个月。
2.根据权利要求1所述的一种用于改善肝硬化营养状态的药膳,其特征在于,是由按重量份计的茯苓7-10份,山药7-10份,薏苡仁7-10份,佛手7-10份,鸡内金3-5份,大枣4-5个,粳米3-5份制成;所述的药膳的加工方法包括以下步骤:
1)按配方选取原料茯苓,山药,薏苡仁,佛手,鸡内金,大枣,粳米,大枣去核后经烘干,备用;
2)将步骤1)的原料用粉碎机加工成粉;
3)在睡前半小时或晚9-10点,将步骤2)加工的粉用开水调成150-200ml米糊饮用;
4)夜间加餐应持续3个月。
3.根据权利要求1所述的一种用于改善肝硬化营养状态的药膳,其特征在于,是由按重量份计的茯苓12-13份,山药12-13份,薏苡仁12-13份,佛手12-13份,鸡内金2-4份,大枣4-5个,粳米4-6份制成;所述的药膳的加工方法包括以下步骤:
1)按配方选取原料茯苓,山药,薏苡仁,佛手,鸡内金,大枣,粳米,大枣去核后经烘干,备用;
2)将步骤1)的原料用粉碎机加工成粉;
3)在睡前半小时或晚9-10点,将步骤2)加工的粉用开水调成150-200ml米糊饮用;
4)夜间加餐应持续3个月。
4.根据权利要求1所述的一种用于改善肝硬化营养状态的药膳,其特征在于,是由按重量份计的茯苓8份,山药8份,薏苡仁8份,佛手8份,鸡内金4份,大枣6个,粳米7份制成;所述的药膳的加工方法包括以下步骤:
1)按配方选取原料茯苓,山药,薏苡仁,佛手,鸡内金,大枣,粳米,大枣去核后经烘干,备用;
2)将步骤1)的原料用粉碎机加工成粉;
3)在睡前半小时或晚9-10点,将步骤2)加工的粉用开水调成150-200ml米糊饮用;
4)夜间加餐应持续3个月。
5.根据权利要求1所述的一种用于改善肝硬化营养状态的药膳,其特征在于,是由按重量份计的茯苓14份,山药14份,薏苡仁14份,佛手14份,鸡内金3份,大枣4个,粳米4份制成;所述的药膳的加工方法包括以下步骤:
1)按配方选取原料茯苓,山药,薏苡仁,佛手,鸡内金,大枣,粳米,大枣去核后经烘干,备用;
2)将步骤1)的原料用粉碎机加工成粉;
3)在睡前半小时或晚9-10点,将步骤2)加工的粉用开水调成150-200ml米糊饮用;
4)夜间加餐应持续3个月。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610128556.8A CN105663900B (zh) | 2016-03-08 | 2016-03-08 | 一种用于改善肝硬化营养状态的药膳 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610128556.8A CN105663900B (zh) | 2016-03-08 | 2016-03-08 | 一种用于改善肝硬化营养状态的药膳 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105663900A CN105663900A (zh) | 2016-06-15 |
CN105663900B true CN105663900B (zh) | 2019-12-20 |
Family
ID=56307736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610128556.8A Active CN105663900B (zh) | 2016-03-08 | 2016-03-08 | 一种用于改善肝硬化营养状态的药膳 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105663900B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109999169A (zh) * | 2019-04-19 | 2019-07-12 | 洪宜超 | 一种用于治疗肝硬化的中药组合物 |
CN115088822A (zh) * | 2022-06-02 | 2022-09-23 | 合肥师范学院 | 一种用于辅助治疗代偿期乙肝后肝硬化的蔬果昔及制作方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102727819A (zh) * | 2012-07-05 | 2012-10-17 | 陈光明 | 治疗消化系统疾病的保康灵多元益生素口服液及制备方法 |
CN104351768A (zh) * | 2014-10-22 | 2015-02-18 | 重庆市大足区季家镇卫生院 | 一种健胃消食药膳 |
CN104997021A (zh) * | 2015-06-19 | 2015-10-28 | 重庆市康泽科技开发有限责任公司 | 白果猪手药膳及其制作方法 |
-
2016
- 2016-03-08 CN CN201610128556.8A patent/CN105663900B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102727819A (zh) * | 2012-07-05 | 2012-10-17 | 陈光明 | 治疗消化系统疾病的保康灵多元益生素口服液及制备方法 |
CN104351768A (zh) * | 2014-10-22 | 2015-02-18 | 重庆市大足区季家镇卫生院 | 一种健胃消食药膳 |
CN104997021A (zh) * | 2015-06-19 | 2015-10-28 | 重庆市康泽科技开发有限责任公司 | 白果猪手药膳及其制作方法 |
Non-Patent Citations (1)
Title |
---|
余绍源教授运用滋水清肝饮治验4则;林穗芳等;《新中医》;20070731;第39卷(第07期);82-83 * |
Also Published As
Publication number | Publication date |
---|---|
CN105663900A (zh) | 2016-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101912559B (zh) | 一种补肾壮阳、养颜及治疗不孕不育的中药丸 | |
CN107897604A (zh) | 一种缓解体力疲劳的西洋参饮品制备方法 | |
CN111249355A (zh) | 一种预防和/或治疗失眠的中药穴位敷贴及其应用 | |
CN105663900B (zh) | 一种用于改善肝硬化营养状态的药膳 | |
WO2014079395A1 (zh) | 一种可以提高免疫力的油类混合物 | |
CN103920102B (zh) | 一种治疗原发性低血压的中药药物 | |
CN114224998B (zh) | 一种治疗脾肾阳虚型功能性消化不良的中药组合物、制剂与应用 | |
CN107125751A (zh) | 龟粉、制备方法及其应用 | |
CN108935694A (zh) | 一种具有抗疲劳兼补血虚的保健羊奶粉及其制备方法 | |
CN105559076A (zh) | 一种备孕期男性全营养药膳餐糊 | |
CN111588029A (zh) | 一种黄精膏组合物 | |
CN105707538A (zh) | 一种适用妇女食用的营养粉条 | |
CN114191514B (zh) | 一种用于预防和治疗痰湿型肥胖症的中药组合物 | |
CN104799360B (zh) | 改善肿瘤患者术后免疫功能的保健汤 | |
CN118403116B (zh) | 一种改善肥胖的药物组合物及其制备方法 | |
CN101653495B (zh) | 治疗失眠的中药药物 | |
CN102671052B (zh) | 治疗美尼尔氏综合症的中药组合物 | |
ZHANG et al. | Twenty-eight cases of simple obesity of spleen and kidney yang deficiency pattern/syndrome in females treated with electroacupuncture and isolated-medicinal moxibustion | |
CN1112204C (zh) | 治疗咳嗽的中药散剂及其制造方法 | |
CN106110179A (zh) | 一种治疗阴虚内热证型悬饮病的中药 | |
CN104888129A (zh) | 一种用于治疗胸痹心痛和高脂血症的中药组合物及其用途 | |
CN105663828A (zh) | 一种用于治疗产后抑郁症的药物及制备方法 | |
CN104971210A (zh) | 治疗脚癣的外洗剂及其制备方法 | |
CN104366481B (zh) | 一种补肾益气药膳的制备工艺 | |
CN104771616A (zh) | 一种治疗神经衰弱的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |